EU First To Approve Novartis’s Cholesterol Drug Leqvio

Twice Yearly Dosing Is Key Selling Point

 
• By Andrew McConaghie
Novartis_Building
Novartis is banking on Leqvio becoming a cardiovascular blockbuster.

More from Cardiovascular

More from Therapeutic Category